Member Info for LlamaFarmer

There are no weak links in this Board of Directors...

The Science is top notch.

The Financial investors, again are top notch.

During her 30-year tenure at Roche, Dr. Crome progressed through increasingly senior roles, ultimately becoming Deputy Head of Early Development & Global Head of Development Operations. In this capacity, she led a team of over 250 professionals and managed a portfolio of more than 100 early development programmes across several therapeutic areas, including CNS, a key area of focus for Solvonis.

Dr. Crome's strategic leadership has been pivotal in the commercialisation of several blockbuster drugs, including leading the prioritisation of Avastin® and Tamiflu®, resulting in rapid regulatory approvals and the realisation of US$7 billion and US$3 billion peak annual sales respectively for Roche. These achievements reflect her ability to drive the development of impactful treatments, especially in therapeutic areas closely aligned with Solvonis's commitment to addressing mental health and addiction.

Currently, Dr. Crome consults for Novo Nordisk ( AKA - OZEMPIC ), advising on early-stage drug development strategies, and previously led the UK Government's UKRI-sponsored COVID-19 treatments programme.

VS,

You notice the extra info dropped in...

Programs in AUD PTSD & comorbid neuro disorders - massive unmet needs in those as well.

And the BIG For Sale sign?

"If you're interested in partnering, collaborating or learning more visit Solvonis.com ."

If you are on Telegram dm Frogger for full link or put that in front of the link below

T . m e /

*************+8fd4qmxncorkymm0

notes on the company to be used for new entrants / refresher over why we are holding.

brief background to awakn & gpl that then formed svns

bod members and experience

articles, research notes

fresh research welcomed

different format to a chat group / echo chamber.

Presenting with this organisation.

https://vetsolutions.org/

PTSD for USA forces, founder is ex seal team, 13 years.

Currently ex servicemen have to travel abroad to receive their Psychedelic treatment, Professors Nutt's workaround with low doseage Esketamine and copywritten therapy after care can help solve this connundrum.

David Nutt is Presenting 16 - 20th June ( now )

The pharmaceutical industry in the US has varying price-to-earnings (PE) ratios depending on the specific segment and company. While the overall US stock market has a PE ratio of around 24.21, the pharmaceutical sector can have significantly higher ratios, particularly within biotechnology and specialized drug categories. For example, the Biotechnology industry has a PE of 53.23, and the Pharmaceutical industry has a PE of 129.64, according to NYU Stern data. This indicates a higher valuation relative to earnings compared to other sectors.

NHS funded the majority of this study - Why?

Alcohol-related harm is estimated to directly cost the National Health Service (NHS) £3.5 billion each year

If SVNS has a 86% treatment rate, 86% of £3,5B is £ 3.10B if SVN 001 removes 86% of this recurring annual cost then what is the instant P.E. value of SVNS?

U.K. Pharma price to earnings ratios - The industry is trading at a PE ratio of 25.9x which is lower than its 3-year average PE of 34.4x

What is 25 X £3B ?

In the UK more than half a million adults have alcohol problems. But only one in five people with alcohol problems get treatment. Even of those who quit alcohol, three out of four will be back drinking heavily after a year. Alcohol-related harm is estimated to cost the UK National Health Service around £3.5 billion each year and wider UK society around £40 billion. Alcohol problems affect not only the individual but families, friends and communities. Alcohol-related deaths have increased still further since the pandemic and we urgently need new treatments. We recently finished a small clinical trial in 96 people with severe alcohol problems. The treatment was three doses of ketamine given through a drip combined with seven sessions of psychological therapy. We found that the drug ketamine could reduce drinking six months after the start of treatment when compared to an inactive drug (placebo). The study also found that giving psychological therapy combined with ketamine reduced drinking still further than when the drug was given without psychological therapy

Any importantly for the USA and for this new FDA fast track programme.

Low Doseage ketamine

Esketamine Novel compound

Large body of supporting work and previous projects data from elsewhere ( under FDA rules and regs ) that can be subsumed into the lead data set.

DVharrison - for me, this is a massive buy and hold, obviously from 13 to 25 you could derisk and many have as the volumes, price action and hot/cold posting history shows, tbh it's sensible to do that on small caps.

Every now and again something comes along that bucks the trend here's hopium this is one of them.

FDA Fast track

Novel Drug ✅

Unmet Public Health Need ✅

None of current 3 treatments side effects ✅

Chairman - US Citizen Dennis Purcell of $15B Life Sciences Aisling Capital ✅

CSO - Prof David Nutt presenting 16 - 20 in Denver ✅

Note - only applicable for Novel treatments - thanks to Professor Nutt SVNS meets this criteria.

Professor Nutt presenting in the USA 16 - 20th June.

https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests

The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. The new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission.

The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists who will pre-review the submitted information and convene for a 1-day “tumor board style” meeting.

“Using a common-sense approach, the national priority review program will allow companies to submit the lion’s share of the drug application before a clinical trial is complete so that we can reduce inefficiencies. The ultimate goal is to bring more cures and meaningful treatments to the American public,” said FDA Commissioner Marty Makary M.D., M.P.H. “As a surgical oncologist, we often made multidisciplinary decisions with a team of doctors on major life-and-death questions for patients, incorporating the latest medical studies in a 1-day tumor board-style discussion. This voucher harnesses that model to deliver timely decisions for drug developers

USA complaint in 2025?

USA FDA just did this ( yday)

https://x.com/US_FDA/status/1934990195515883865

U.S. FDA

@US_FDA

·

15h

This program aims to accelerate the drug review process for companies aligned with U.S. national priorities while maintaining the FDA's rigorous standards for safety, efficacy, and quality.

And an earlier post also links to our new Ai into the CNS library

U.S. FDA

@US_FDA

Today at #DIA2025,

@DrMakaryFDA

participated in a key panel discussion on FDA modernization. He highlighted how AI and big data are revolutionizing our approach and accelerating development and approval of life-saving treatments. The future of healthcare is data-driven and patient-centric.

Probably time to buy?

DVH

No, nothing, apart from...

Soft news flow guaranteed ...

U.S.A

Professor Nutt - Denver U.S.A. 4th Annual Psychedelic discussing his Solvonis and Imp College work 16- 20th, Nutt listed as a speaker on main page along with picture on web page of key note speakers.

Join a global community of over 7,000 attendees and more than 600 speakers as we come together to shape the future of mental health, medicine, and consciousness

U.K.

AGM - 24th - Anthony Tennyson

U.K.

Proactive 27th June - Anthony Tennyson

Hard News flow

U.S.A

Phase 2 Esketamine trial update ?

U.K.

July update Multicentre Investigation of Ketamine for Reduction of Alcohol Relapse aka More-Care

Then there is this library of CNS data, they have sold licences to products previously, and Professor Nutt is prolific in his work rate, there is the potential for income streams to be generated prior to the NHS and FDA payments?

Interesting that Pamlico Shoals took 12.36% wasn't it? £1m they put in at 0.13p.

Where are they based, what other businesses do they run? Where is their client and customer base?

Jollifant,

If you looked at it yesterday morning, you couldn't sell as many as you could buy, the MM's ran it up and let everyone buy, now they have run it back down to just above where it started from last Friday and are gathering them all back in, to anyone that sold - great, to anyone that bought equally - great just hold them.

End of June signals the start of July - will be warming up...

Who is the consultant at Novo Nordisk again? Would they know about growing pipeline Phase 2b and 3 drugs?

Phase 2b is in the USA isn't it? HOW will they start to advertise what they have got coming into the American market?

I keep looking at Novo Nordisk and Ozempic and wonder what that would look like?

What's the saying, in for a penny in for a ??

All about the churn at the moment... 13, 18, 25 not as relevant.

Once they decide to turn this hot, 0.25p will look 'cheap'

The previous raise at 0.10 has already churned, that is how they got the next raise at a 30% mark up.

This last raise had to last them for 12 calendar months after the purchase of Awakn.

Fully funded

Placing Churned

Owns all the IP

Worth researching

Then you need to consider that Pamlico Shoals ( TR1 RNS still outstanding from the 27th May )

Owns 730M shares or £1m and only appeared in the Prospectus at the time of this new raise so if you take that off of the placing amount there are only 808m shares 'floating' about and in that case the placing has already turned over approx 2.16 times.

You generally want to see 2.5 - 3 X churn imo.

But what you also need to take off is the stock that went to Anthony Tennyson, Professor Nutt, Dennis Purcell, Ryan Neates ....

Personally I think the traders have done well and the holders are shortly to take their turn.

RNS 16th May.

the Company has conditionally raised gross proceeds of approximately £2.0 million (the "Fundraise") through the proposed issue of 1,538,461,529 new ordinary shares of £0.001 each in the Company (the "Fundraise Shares") with certain existing and new institutional and other investors at the Issue Price of 0.13 pence per Fundraise Share.

Admission and Total Voting Rights

Application will be made for the 3,612,840,057 Fundraise Shares and Consideration Shares, as defined in the Fundraise Launch Announcement

Following Admission, the Company's enlarged issued ordinary share capital will comprise 5,908,770,690 ordinary shares.

'New' Stock of 1,538,461,529 X 0.13p ( the placing price ) = £2,000,000 ( the amount raised )

So the placing has already churned over 1.25 times comparing the new stock issued vs stock turnover since the date of issue.

As it becomes tighter it will react upwards to the next positive news flow.